New pill could help asthma sufferers breathe easier
NCT ID NCT07191535
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug, linvemastat, for adults with moderate-to-severe asthma that is not fully controlled by standard inhalers. About 135 participants will receive either one of two doses of linvemastat or a placebo, while continuing their usual medications. Over 16 weeks, researchers will measure lung function, symptom control, and safety to see if linvemastat can offer a new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
linvemastat (FP-020)
What this could lead to
If it works, this could lead to a new daily pill to help control moderate-to-severe asthma and reduce flare-ups.
What could go wrong
This is an early phase 2 trial with only 135 people, so results may not apply to everyone. The drug may not improve lung function or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA (DIAGNOSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••